US Cancer Generics Market Set for Further Growth, According to Kuick Research Report Published at MarketPublishers.com
14 Mar 2017 • by Natalie Aster
LONDON – Stake holders active in the US cancer drug marketplace have saved billions of dollars thanks to the introduction of generics. The overall savings from the generic in cancer therapy are set to surpass the USD 30 billion mark by 2020.
There is a wide gap between patented oncological drugs and the generic ones, but it is becoming shorter.
Still, the costs of cancer generics in the U.S. are higher than in other countries due to the absence of agreement between the local government and the pharma sector. In China, for instance, the costs are many fold lower.
The prescription and usage of generics are higher than in developing countries given greater medical needs.
There is scarcity of generics across all the medical specialties, but the worst situation is observed in the oncology sector.
In-demand research report “US Cancer Generics Market Outlook 2022” drawn up by Kuick Research provides a comprehensive discussion of the US cancer generics drug landscape. The study starts with a detailed introduction to the generic drugs landscape.
It throws light on the US legislature pertinent to the generics. The report examines the economic burden this industry faces in the US. The research study concentrates on pricing issues.
It scrutinizes the local health insurance scenario, with special attention paid to cancer. The research report limelights aspects of both branded and non-branded generics. The study explores the role of generics in the oncology world.
It focuses on anti-cancer generics that received approval from FDA. The report proceeds with a 360-degree overview of the US cancer generics marketplace. The research study casts light on the market dynamics. Future prospects of the marketplace are also scrutinized in the report.
More insightful research studies by Kuick Research can be found at its page.